159 related articles for article (PubMed ID: 15507576)
1. Tenofovir, equivalence, and noninferiority.
Parienti JJ
JAMA; 2004 Oct; 292(16):1951; author reply 1951-2. PubMed ID: 15507576
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir ready for approval.
AIDS Patient Care STDS; 2001 Jul; 15(7):399. PubMed ID: 11483167
[No Abstract] [Full Text] [Related]
4. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Dec; 286(21):2660. PubMed ID: 11730423
[No Abstract] [Full Text] [Related]
5. Tenofovir-related nephrotoxicity in HIV-infected patients.
Barrios A; García-Benayas T; González-Lahoz J; Soriano V
AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
[No Abstract] [Full Text] [Related]
6. Tenofovir disoproxil fumarate.
Kumar A
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887267
[No Abstract] [Full Text] [Related]
7. Tenofovir disoproxil fumarate.
Antoniou T
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
[No Abstract] [Full Text] [Related]
8. Summaries for patients. Treatment for resistant HIV-1 infection.
Ann Intern Med; 2003 Sep; 139(5 Pt 1):I22. PubMed ID: 12965954
[No Abstract] [Full Text] [Related]
9. Tenofovir gel studied.
AIDS Patient Care STDS; 2002 Aug; 16(8):401-2. PubMed ID: 12227991
[No Abstract] [Full Text] [Related]
10. [Further indications for tenofovir].
Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207
[No Abstract] [Full Text] [Related]
11. Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Thompson CA
Am J Health Syst Pharm; 2002 Jan; 59(1):18. PubMed ID: 11813460
[No Abstract] [Full Text] [Related]
12. Encouraging results for tenofovir.
AIDS Patient Care STDS; 2001 May; 15(5):289. PubMed ID: 11530770
[No Abstract] [Full Text] [Related]
13. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
Domingo P; Labarga P; Palacios R; Guerro MF; Terrón JA; Elías MJ; Santos J; Ruiz MI; Llibre JM;
AIDS; 2004 Jul; 18(10):1475-8. PubMed ID: 15199328
[TBL] [Abstract][Full Text] [Related]
14. Cambodia: can a drug provide some protection?
Cohen J
Science; 2003 Sep; 301(5640):1660-1. PubMed ID: 14500956
[No Abstract] [Full Text] [Related]
15. The continuing evolution of HIV therapy.
Boyle BA
AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
[No Abstract] [Full Text] [Related]
16. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Feinberg J
AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
[No Abstract] [Full Text] [Related]
17. PMPA trials recruiting.
AIDS Treat News; 1998 Sep; (303):5-6. PubMed ID: 11365766
[TBL] [Abstract][Full Text] [Related]
18. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
19. Can AIDS drug also prevent HIV infection?
AIDS Read; 2004 Jan; 14(1):14. PubMed ID: 14959699
[No Abstract] [Full Text] [Related]
20. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, 28-31 October 2001.
Palfreeman A; Huengsberg M
Sex Transm Infect; 2002 Apr; 78(2):149. PubMed ID: 12081181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
